Latest News on Sun Pharma
Sun Pharma receives green light for obesity treatment injection similar to Wegovy.
Sun Pharmaceutical Industries has received approval for a weight loss injection similar to Novo Nordisk’s Wegovy. The new treatment, called “SUN-144”, is a once-weekly injection that helps with weight management in adults with obesity or overweight with at least one weight-related condition. This approval marks a significant milestone for Sun Pharma, as it enters the growing market for anti-obesity treatments.
Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been highly successful in treating obesity, with sales exceeding $1 billion in 2022. SUN-144 is also a GLP-1 receptor agonist, which works by mimicking a natural hormone that helps regulate appetite and food intake. Clinical trials have shown that SUN-144 is effective in reducing body weight and improving glycemic control in patients with type 2 diabetes.
The approval of SUN-144 is expected to increase competition in the anti-obesity market, which is currently dominated by Novo Nordisk’s Wegovy and Saxenda. However, Sun Pharma’s entry into the market may also lead to increased accessibility and affordability of these treatments, which could benefit patients who struggle with obesity and related health conditions.
Sun Pharma’s SUN-144 has shown promising results in clinical trials, with significant weight loss and improvements in cardiovascular risk factors. The treatment has also been well-tolerated, with common side effects including nausea, vomiting, and diarrhea. As the global prevalence of obesity continues to rise, the demand for effective and safe treatments is increasing. Sun Pharma’s entry into the market is expected to help meet this demand and provide patients with more options for managing their weight and related health conditions.
The approval of SUN-144 is a significant achievement for Sun Pharma, which has been expanding its portfolio of specialty and generic products. The company has a strong presence in the pharmaceutical industry, with a global footprint and a wide range of products. With the launch of SUN-144, Sun Pharma is poised to become a major player in the anti-obesity market, which is expected to continue growing in the coming years. As the company prepares to launch SUN-144, it is likely to focus on educating healthcare professionals and patients about the benefits and risks of the treatment, as well as its potential to improve health outcomes for individuals with obesity and related conditions.
Several major Indian pharmaceutical companies, including Sun Pharma, Cipla, Zydus, and Graviti, have issued recalls for certain medications in the United States market.
Several major pharmaceutical companies, including Sun Pharma, Cipla, Zydus, and Graviti Pharmaceuticals, are recalling various products in the US due to manufacturing issues, according to recent US FDA enforcement reports. The recalls are primarily related to problems with impurities, quality control, and production processes.
Sun Pharma is recalling over 24,000 bottles of Fluocinolone Acetonide topical solution and Clindamycin Phosphate topical solution due to out-of-specification results for impurities and assay. Cipla is recalling more than 15,000 syringes of Lanreotide Injection, used to treat a rare hormonal condition, due to production issues at its Greek manufacturing partner, Pharmathen. The production of Lanreotide has been temporarily paused to address quality concerns, resulting in limited supply.
Additionally, Cipla is recalling over 92,000 tubes of Diclofenac Sodium Topical Gel due to failed pH specifications. Graviti Pharmaceuticals is recalling over 4,000 bottles of Furosemide Tablets due to the presence of a foreign substance. Zydus Pharmaceuticals is recalling over 22,000 bottles of Icosapent Ethyl capsules due to oxidation caused by leakage, which may lead to inconsistent therapeutic effects and increased gastrointestinal side effects.
These recalls highlight the importance of quality control and manufacturing standards in the pharmaceutical industry. The FDA’s enforcement actions aim to ensure that products meet strict safety and efficacy standards to protect public health. The recalls may result in temporary shortages of these products, and patients are advised to consult their healthcare providers for alternative treatments.
The recalls also underscore the need for pharmaceutical companies to maintain robust quality control systems and adhere to good manufacturing practices (GMPs) to prevent such issues. The companies involved are taking corrective actions to address the problems and prevent future occurrences. The FDA will continue to monitor the situation and take further action if necessary to ensure the safety and efficacy of pharmaceutical products in the US market.
Sun Pharma receives DCGI approval for generic version of Wegovy, plans March release ahead of Semaglutide patent expiration.
Sun Pharmaceutical Industries has received approval from the Drugs Controller General of India (DCGI) to launch a generic version of Novo Nordisk’s Wegovy, a medication used to treat obesity. The approval comes as the patent for the active ingredient, semaglutide, is set to expire in March 2023.
Wegovy, which contains semaglutide, is an injectable glucagon-like peptide-1 (GLP-1) receptor agonist that helps with weight loss in adults with obesity. The medication has been shown to be effective in reducing body weight and improving glycemic control in patients with type 2 diabetes.
Sun Pharma’s generic version of Wegovy will be launched in India in March, coinciding with the patent expiry of semaglutide. The company has been working on developing a generic version of the medication for some time and has completed the necessary clinical trials and regulatory requirements to obtain approval from the DCGI.
The launch of Sun Pharma’s generic Wegovy is expected to increase access to this medication for patients in India, where obesity is a growing health concern. According to the World Health Organization (WHO), India has one of the highest rates of obesity in the world, with over 30% of the population classified as obese.
The generic version of Wegovy is also expected to be more affordable than the branded version, making it more accessible to patients who may not have been able to afford the medication otherwise. Sun Pharma’s entry into the market is likely to increase competition and drive down prices, benefiting patients and healthcare systems.
Novo Nordisk’s Wegovy has been a blockbuster medication, with sales of over $1 billion in 2022. The patent expiry of semaglutide is expected to lead to a significant increase in the availability of generic versions of the medication, which could impact Novo Nordisk’s sales. However, the company has a strong pipeline of new medications and is expected to continue to be a major player in the pharmaceutical industry.
Overall, the approval of Sun Pharma’s generic Wegovy is a significant development for patients in India, who will now have access to an affordable and effective treatment option for obesity. The launch of the generic medication is also expected to increase competition in the market, driving down prices and benefiting healthcare systems.
Stock Market Updates for Sun Pharma
Recent Updates
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.